Biogen Inc (BIIB)
$195.24-0.59%
Spriggl Score: Moderate— see the number + sub-scores with a free Spriggl account
Last 30 trading days
Spriggl AI Verdict
“May 2026 Leqembi self-injector is the pivotal catalyst; deep value at 11.7x P/E if the franchise accelerates.”
Sign up free to read the full investment thesis, bull case, bear case and what to watch.
About Biogen Inc
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCL…
- Sector:
- Healthcare
- Industry:
- Drug Manufacturers - General
- Market Cap:
- $28.5B
Recent dividends
No recent dividends recorded.
Get the full Spriggl analysis — free
Sign up for a free Spriggl account to unlock the full Spriggl Score breakdown, screener, watchlist, and AI investment analysis on Biogen Inc and 1,600+ UK and US stocks.
Start free